Acquired Aplastic Anemia
Jun 3, 2025

What is Acquired Aplastic Anemia
Often caused by various external insults. Incidences like western countries have 2-6 cases/million population/year. In Asia, there are a higher number of incidents. In Japan it was noticed up to 14-15 cases/million population/year. Mechanism implicated:
- Direct injury to HSCs
- Immune mechanism
- Abnormal BM environment which disfavours hematopoiesis.
Etiology
- In children, many cases are Idiopathic
- Radiation can be a significant cause
- Drugs can also have a role in it
- Viruses: CMV, EBV, HBV, HCV HIV (Rare)
- Pregnancy
- Immune diseases: Thymoma, Eosinophilic Fasciitis, Hypogammaglobulinemia
- PNH
- Marrow replacement: Leukemia, MDS, Myelofibrosis
- Nutritional deficiency: Vitamin B12, Folic Acid (Rarely)
- Autoimmune
- Cryptic dyskeratosis congenita (no physical stigmata)
- Telomerase reverse transcriptase haploinsufficiency
Dose-dependent toxicity
- Antimetabolites and alkylkating agents.
- Cytotoxic antibiotics
- Etoposide, vinblastine, paclitaxel
- Colchicine, insecticides, benzene
Dose-independent/idiosyncratic
- Antibiotics (Methicillin, Tetracyclin and Chloramphenicol)
- NSAIDs, Gold
- Antiepileptic Agents: Valproate, Ethosuximide, CBZ
- Quinidine
- Diuretics
- Chlorpropamide, Tolbutamide
- Anti-thyroid drugs
- Antihypertensives: ACEIs, Methyldopa (Rare)
Laboratory findings
- ↓ HCT
- ↓ Reticulocyte count
- ↓ TLC, ↓ ANC
- ↓ Platelet count
- BM: Cellularity (<30%) especially in severe, symptomatic cases
- Flow cytometry
- CD55
- CD59
- Macrocytic or Normocytic - Normochromic picture of RBCs.
Categories of Aplastic Anemia
- Essential: BM Cellularity <30% on biopsy
- Moderate AA- When ≥2 of the following are present
- ANC: 500-1500/mm3
- Platelets: 20000 to 1 Lakh/mm3
- Reticulocyte Count < 1% after correction for Hematocrit
- Severe AA: When ≥2 of the following are present
- ANC: <500/ mm3
- Platelets: <20000/mm3
- Reticulocyte Count <1% after correction for Hematocrit
Complications in Aplastic Anemia
- Severe Anemia: CCF
- Recurrent infection: Bacterial/ Viral/ fungal
- Life threatening hemorrhage
Treatment
- Moderate AA: Supportive care + observation with close follow up. 65% of moderate cases progress to severe forms.10-15% remain the same and remaining show spontaneous remission where drug induced effects tend to improve with time. Severe Aplastic Anemia
- Allogenic BM/ HSCT when HLA-matched sibling donor is available (20-25%) - is the therapy of choice
- Preparative regimen incorporates cyclophosphamide, Fludarabine and ATG
- Alternative for preparation and conditioning is Alemtuzumab
- Risks pertaining to BMT are the usual ones
- If Donor N/A in Severe AA- Use Immunosuppressants. Cyclosporine + ATG: Response rate of 70-80% in 6 months. In relapse (30%), can repeat the regimen. G-CSF added in severe neutropenia: If > 7 days of a stretch → Malignancy. If there is no response to Immunosuppressants/Serious Side Effects we need to use alternate therapy.
- HLA-matched unrelated BMT or Cord blood transplant
- High-dose Cyclophosphamide with/without cyclosporine
Newer Therapies for Refractory AA
- Eltrombopag
- Alemtuzumab (Anti-CD52)
Prognosis
Spontaneous recovery from pancytopenia rarely occurs. If left untreated, severe pancytopenia has an overall mortality rate of approximately 50% within 6 months of diagnosis and of >75% overall. Infection and hemorrhage are the major causes of morbidity and mortality. Children responding to HSCT and/or immunosuppressive regimens early usually have a good outcome. 65-70% have good survival if they come to early attention.
Hope you found this blog helpful for your E-learning for NEET SS Pediatrics. For more informative and interesting posts like these, keep reading PrepLadder’s blogs.
Download the PrepLadder app and get online coaching with world-class video lectures, QBank, Mock Tests and more!

PrepLadder Medical
Get access to all the essential resources required to ace your medical exam Preparation. Stay updated with the latest news and developments in the medical exam, improve your Medical Exam preparation, and turn your dreams into a reality!
Navigate Quickly
What is Acquired Aplastic Anemia
Etiology
Dose-dependent toxicity
Dose-independent/idiosyncratic
Clinical findings in Acquired Aplastic Anemia
Laboratory findings
Categories of Aplastic Anemia
Complications in Aplastic Anemia
Progression to malignancy
Treatment
Newer Therapies for Refractory AA
Prognosis
PrepLadder 4.0 for NEET SS
Avail 24-Hr Free Trial
.png)